Oral Inosine does not slow progression of early Parkinson disease
Sep 16, 2021
No significant difference seen in rate of clinical disease progression or in secondary efficacy outcomes versus placebo
Clinical briefs for Wednesday, Sept. 15
Sep 15, 2021
Survey: Most seniors approve of healthcare worker vaccinations … Depression levels rose among older adults during pandemic, survey shows … Alzheimer’s advocates urge HHS to adopt ‘aggressive’...
Scientists grow ‘mini brains’ that mimic Parkinson’s disease
Sep 09, 2021
For the first time, scientists have grown tiny brains in laboratory dishes that mirror the major pathological features of Parkinson’s disease. The research offers a new way to learn how the disease progresses...
Clinical briefs for Tuesday, Aug. 24
Aug 24, 2021
New ethics standards published for dementia caregivers … Parkinson’s disease quality measurement set update released … Early, awake prone positioning reduces intubation risk in acute COVID patients:...
Clinical briefs for Thursday, Aug. 19
Aug 19, 2021
Nursing homes recaptured $32M after reducing hospitalizations: study … Telehealth plus wearable tech allows better Parkinson’s symptom management … Non-invasive scan tech could help assess effectiveness...
Relapse risk for psychosis in dementia lower with continued pimavanserin
Jul 22, 2021
Findings seen in double-blind, randomized, placebo-controlled discontinuation trial that was stopped early for efficacy
Weekly dance training can help slow Parkinson’s progression, study finds
Jul 19, 2021
Parkinson’s patients who participated in dance training with music for 1.25 hours per week had improved Parkinson’s symptoms compared with those who did not do any dance exercise, a new study published...
Clinical briefs for Monday, June 14
Jun 14, 2021
3 FDA advisory panel members resign in wake of controversial approval of new Alzheimer’s drug … U.S. suspends COVID J&J vaccine shipments as backlog builds; extends expiration dates … VoiceFriend...
Brain implants continue to reduce Parkinson’s motor symptoms 15 years later
Jun 11, 2021
The amount of time study participants experienced dyskinesia was reduced by 75%, and use of levodopa was reduced by 51% — long after deep brain stimulation devices were implanted.
Clinical briefs for Wednesday, May 26
May 26, 2021
The true scope of COVID? 20% of hospitalized patients not discharged to home … HHS re-ups provider reimbursement for testing uninsured patients for COVID … Feds, nonprofits surpass big pharma in Alzheimer’s...